These results indicate that dasatinib and radotinib function as an HSP90 inhibitor in AML cells regulated HSP90β activity and expression in c-KIT-positive AML cells that contributed to c-KIT-positive AML cell death (Supplementary Fig. 3, Supplementary Fig. 5 and Fig. 6). The gene discussed is HSP90AB1; the disease is acute myeloid leukemia.